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Half of invasive fungal infections lead to death. Amongst pathogenic fungi, the most
widespread species belong to the Candida genus and vary in their susceptibility to
antifungal drugs. The emergence of antifungal resistance has become a major clinical
problem. Therefore, the definition of susceptibility patterns is crucial for the survival
of patients and the monitoring of resistance epidemiology. Although, most routinely
used methods of AntiFungal Susceptibility Testing (AFST) have reached their limits,
the rediscovery of Matrix Associated Laser Desorption/Ionization Time of Flight Mass
Spectrometry (MALDI-TOF MS) in the field of mycology provides a promising alternative
for the study of antifungal resistance. MALDI-TOF MS is already used in mycology for
fungal identification, which permits to highlight inherent antifungal resistance. However,
the main concern of clinicians is the rise of acquired antifungal resistance and the time
needed for their detection. For this purpose, MALDI-TOF MS has been shown to be an
accurate tool for AFST, presenting numerous advantages in comparison to commonly
used techniques. Finally, MALDI-TOF MS could be used directly to detect resistance
mechanisms through typing. Consequently, MALDI-TOF MS offers new perspectives in
the context of healthcare associated outbreaks of emerging multi-drug resistant fungi,
such as C. auris. As a proof of concept, we will illustrate the current and future benefits
in using and adapting MALDI-TOF MS-based assays to define the susceptibility pattern
of C. auris, by species identification, AFST, and typing.
Keywords: MALDI-TOF MS, Candida spp., antifungal resistance, identification, antifungal susceptibility testing,
typing
INTRODUCTION
Fungal infections range from harmless superficial infections to invasive illnesses causing
generalized sepsis and often leading to death (Brown et al., 2012). Invasive fungal infections are
of great concern for clinicians because of the high mortality rate, which reaches up to 50% of
patients (Brown et al., 2012). Most of these infections are caused by opportunistic pathogens
that take advantage of immunosuppression (HIV/AIDS or cancer patients), even though they are
commensal in healthy individuals (Brown et al., 2012). The most prevalent fungal pathogens of
invasive infections in these high-risk patients belong to the Candida genus (Brown et al., 2012).
Moreover, they are the fourth most common cause of nosocomial bloodstream infections. Among
Candida species (spp.), C. albicans is the most prevalent infectious fungus, being responsible for
50–70% of invasive candidiasis (Sanguinetti et al., 2015).
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In this review, we will present the current methods used
to define the susceptibility patterns of Candida spp., by
species identification and thus the definition of the inherent
susceptibility pattern and by in vitro Antifungal Susceptibility
Tests (AFST). We will then illustrate how Matrix Associated
Laser Desorption/Ionization Time of Flight Mass Spectrometry
(MALDI-TOF MS) could be a promising alternative to the
routine methods.
FUNGAL INFECTIONS AND ANTIFUNGAL
RESISTANCE
Treatment of Fungal Infections and
Emergence of Antifungal Resistance
Fungal infections can be treated using four main drug classes:
azoles, polyenes, pyrimidine analogs, and echinocandins. The
first two types of drugs disrupt cell membrane integrity, the
third destabilizes nucleic acids whereas the last prevents cell
wall biosynthesis (Sanglard, 2016). Precisely, azoles, one of the
most broadly used antifungal drug classes, inhibit ergosterol
biosynthesis by targeting lanosterol 14-α-sterol demethylase,
encoded by the ERG11 gene in C. albicans. This enzyme
participates in the conversion of lanosterol to ergosterol,
the latter being involved in the cell membrane integrity. By
inhibiting the lanosterol 14-α-sterol demethylase, azoles induce
the accumulation of a toxic sterol compound, disturbing the
fungal cell membrane, leading to growth inhibition (Vandeputte
et al., 2012; Sanguinetti et al., 2015). Polyenes bind ergosterol
itself, leading to a membrane leakiness, which causes cell
death. Finally, Echinocandins bind to β-(1,3)-glucan synthase,
inhibiting cell wall synthesis, which also lead to cell death
(Sanglard, 2016).
However, as suggested by the high mortality rates, antifungal
drugs such as azoles, are not always effective. Indeed, some
fungal species are inherently resistant to specific antifungal
drugs. Therefore, species identification is crucial and should
rapidly be done to select appropriate treatments. Moreover,
during long-term treatment, some fungi can acquire new
antifungal resistances mechanisms. Even if such resistance is rare
among fungi (1–4%), especially in C. albicans (1–2% in 2011)
(Cleveland et al., 2012; Sanguinetti et al., 2015), theymake patient
treatment more challenging and need to be rapidly detected. It is
particularly important in the case of azole resistance, which has a
higher incidence than echinocandin resistance, probably because
of the azole fungistatic vs. echinocandin fungicidal properties
against Candida spp. (Vandeputte et al., 2012).
For a more appropriate patient stewardship, we ideally
need to not only rapidly detect the presence of an acquired
antifungal resistance but also identify the mechanism involved.
This is especially relevant in azole resistance, since it was
shown that some resistance mechanisms confer resistance only
to some specific azole(s) whereas others confer cross-resistance
to all azoles (Sanglard et al., 1995). Therefore, depending on
the resistance mechanism identified, the treatment could be
more precisely adjusted. Thankfully, during the last 20 years,
the four main general mechanisms allowing azole resistance
were considerably elucidated (for review, see Vandeputte et al.,
2012). The first mechanism consists in the upregulation, via
transcription factor (TF) gain-of-function (GOF) mutations, of
the expression of ATP-Binding Cassette (ABC) transporters and
Major Facilitator Superfamily (MFS) transporters, two types of
cell wall transporters responsible for drugs extrusion (Coste
et al., 2006; Dunkel et al., 2008). The second mechanism
depends on a mutation in Erg11 drug binding site, decreasing
the fluconazole affinity and altering the fluconazole antifungal
action (Sanglard et al., 1998). The third mechanism involves
a GOF mutation in the TF Upc2, leading to the upregulation
of ERG11 expression and the neutralization of the fluconazole
action (Flowers et al., 2012). The last mechanism is rarer and
relies on yeast metabolism modifications, which inhibits the
production of toxic compounds for the fungi (ex: mutation
in ERG3) (Martel et al., 2010). Echinocandins resistance relies
essentially onmutations of FKS1/FKS2, coding the β-(1,3)-glucan
synthase. Mutations responsible for resistance clustered in two
major hot spots. Those mutations lead to reduced affinity of
the drug for its target and are associated to pan-echinocandins
resistance (Sanglard, 2016).
Current Routine AFST Methods
Fluconazole resistance is assessed in vitro by different Antifungal
Susceptibility Tests (AFST). The quality and reproducibility
of these analyses are ensured by standardized protocols
implemented by the Clinical and Laboratory Standard Institute
(USA, CLSI) and the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) (Posteraro and Sanguinetti,
2014). CLSI and EUCAST shed light on the clinical success
probability for infected patients (Rex et al., 1997; Posteraro and
Sanguinetti, 2014).
There exists 3 principal commercial AFST methods (for
review see Posteraro and Sanguinetti, 2014): ETEST R©
(bioMérieux), SensititreTM YeastOneTM (ThermoFisher
Scientific) and the Vitek R© 2 Yeast susceptibility system
(bioMérieux). The first two are manual minimum inhibitory
concentration (MIC) determination methods. The third is an
automated system extrapolating aMIC value from 2 to 3 measure
points. However, all current routine AFST methods have two
main disadvantages. First, they are time-consuming due to the
yeast generation-time. Indeed, 24 to 48 h are required to obtain
AFST results (Posteraro et al., 2013). Second, results obtained
are subjective, particularly for YeastOneTM; accurate MIC is
difficult to determine and different results can be obtained
depending on the experimenter (Marinach et al., 2009; Posteraro
and Sanguinetti, 2014). Moreover, the correlations between the
clinical breakpoints and the clinical outcomes are not totally
reliable (Delarze and Sanglard, 2015). In the case of candidemia,
the use of molecular methods like PCR-based methods are
not always feasible, even though the mechanisms of antifungal
resistance and the gene involved are known (for review, see
Vandeputte et al., 2012). In the case of azole resistance, a
gene involved in the resistance can be mutated at several
locations (Morio et al., 2010; Ferrari et al., 2011; Vandeputte
et al., 2012), rendering the elaboration of a PCR-based method
laborious or even impossible. Clinical mycology is thus in need
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of new rapid and objective automated methods to establish
the susceptibility level of Candida spp. strains, allowing more
efficient management of candidemia.
MALDI-TOF AND ANTIFUNGAL
RESISTANCE DETECTION
MALDI-TOFMS (for review, see Clark et al., 2013) was first used
in the late 1990s in clinical microbiology on bacteria (Arnold and
Reilly, 1998), since bacterial infections have a higher incidence
and bacteria are easier to work with than fungi. MALDI-TOF
MS was used, with bacteria, for identification (Arnold and Reilly,
1998), Antimicrobial Susceptibility Testing (AST) (Sparbier et al.,
2016) and typing (Arnold and Reilly, 1998; Doern and Butler-
Wu, 2016). Since 2001, with the widespread application of
MALDI-TOFMS in bacteriology, mycologists attempted to adapt
this tool for fungi (Posteraro et al., 2013).
MALDI-TOF MS for Fungal Identification
The first crucial step in the administration of antifungal therapy
is the correct identification of the yeast species. Indeed, as
mentioned above all Candida spp. strains are not all susceptible
to the same antifungal panel. In this context, MALDI-TOF
MS is crucial since its first application in clinical microbiology
is the rapid and accurate identification of microbial species,
especially bacteria (Bader et al., 2011; Posteraro et al., 2013).
In the early 2000s, MALDI-TOF MS was rapidly assessed as
a useful alternative to classical methods for the identification
of not only bacteria but also fungal species (Qian et al.,
2008; Marklein et al., 2009; Cassagne et al., 2016). Fungi were
more challenging to identify because of their cell wall, which
complicates the spectra acquisition. In 2001, protocols were
first adapted with Saccharomyces cerevisiae (Amiri-Eliasi and
Fenselau, 2001). Following this, the idea that MALDI-TOF MS
could be automated for fungal identification emerged (Qian et al.,
2008). Since 2009, MALDI-TOF MS is routinely used for yeast
identification (Marklein et al., 2009; Lee et al., 2011).
To identify a microorganism, the peaks of the experimental
spectrum acquired with MALDI-TOF MS are compared to
signature peaks from reference spectra, contained in databases.
The quality of the identification is dependent on the number
of reference spectra available among other factors such as
sample growth and preparation, fine settings of the machine,
experimenter, etc. (Croxatto et al., 2012). Previous experimental
studies demonstrated that MALDI-TOF MS was less arduous
than routine identification methods like microscopy, automated
blood culture system and biochemical tests to identify Candida
spp (Marinach et al., 2009). It was shown to be a reliable, fast,
and straightforward method compared to conventional ones
that are time-consuming and need trained professionals to be
interpreted (van Veen et al., 2010; Posteraro et al., 2013). As
an illustration, Candida spp. can be identified in a day with
MALDI-TOFMSwhereas othermethods can require up to 4 days
(Fernandez et al., 2009). Moreover, MALDI-TOF MS analysis
was able to differentiate closely related species when conventional
biochemical methods were not such as species of the parapsilosis
complex (C. parapsilosis, orthopsilosis and metapsilosis) (Bader
et al., 2011). Furthermore, MALDI-TOF MS can detect 95.7–
100% of common Candida species like C. albicans, C. glabrata,
C. dubliniensis, and C. tropicalis (Bader et al., 2011; Bille et al.,
2012; Iriart et al., 2012). Accuracy is lower for uncommon species
like C. inconspicua, C. rugosa, and C. norvegensis (73.6–88.9%).
However, when databases are sufficiently extensive and regularly
updated, MALDI-TOF MS could detect these species, whereas
the classical identification method could not (Santos et al., 2011;
Posteraro et al., 2013). Indeed, in all the studies mentioned
above, MALDI-TOF MS identifications are always at least as
good as the classical biochemical identification methods (rapid
latex agglutination, ID32C system (bioMérieux), API 20C AUX
and morphological and carbon source assimilation specificity).
The identification of these uncommon species is essential since
they are known to have more inherent resistance (Rodloff et al.,
2011). Consequently, MALDI-TOF MS offers great benefits in
clinical mycology to bring forward inherent resistance through
rapid yeast/fungi identification, leading to a first assessment of
the antifungal susceptibility level.
MALDI-TOF MS for AFST
The second crucial step in the administration of appropriate
antifungal therapy is the detection of eventual acquired
antifungal resistance.
In 2009, Marinach et al. developed a first MALDI-TOF MS-
based assay to discriminate fluconazole-resistant C. albicans
strains from susceptible ones. Their method is based on the
determination of the minimal profile change concentration
(MPCC) for a given strain, a new alternative endpoint to the
classical MIC. It was shown than MPCC and MIC are correlated,
presenting a discrepancy of maximum 2 dilutions. MPCC is
defined as the minimal drug concentration needed to detect
changes in MALDI-TOF MS spectra. MPCC corresponds to
the minimal concentration at which the result of the cross-
correlation with the spectra at the maximal concentration
(128µg/mL for C. albicans and fluconazole) is higher than
the result of the cross-correlation with the spectra at the
null concentration (0µg/mL) (Figure 1A, right panel; Marinach
et al., 2009). The MPCC determination was then made more
objective and quantitative by De Carolis et al. (2012), using
a composite correlation index (CCI) matrix obtained with the
MALDI Biotyper R© software. The CCI matrix provides scores of
composite correlation between all the MALDI-TOF MS spectra
allowing a quantitative determination of the MPCC, which is
also better visualized (Figure 1A; De Carolis et al., 2012). MPCC
breakpoints were then defined as the minimal antifungal drug
concentration at which all spectra from the known resistant
strains are more similar to the spectra at the null concentration,
whereas all spectra from the known susceptible strains are more
similar to the spectra at the maximal concentration (Figure 1B).
MPCC breakpoints are species and drug-dependent, like the
EUCAST and CLSI breakpoints, and allow to interpret MALDI-
TOF MS AFST results (De Carolis et al., 2012). This new
MALDI-TOF MS-based assay was improved by Vella et al.
(2013). They decreased the exposure time to the antifungal drug
from 15 h (De Carolis et al., 2012) to 3 h and simplified the
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FIGURE 1 | Evolution of the MALDI-TOF MS-based AFST assay. (A) MPCC determination. A 13 × 13 CCI matrix (personal data) is generated by comparing the
spectra obtained after exposure to increasing concentrations of fluconazole (0 = MIN to 256µg/mL = MAX), as explained in De Carolis et al. (2012). Red gradient
corresponds to strong correlations and blue gradient corresponds to weak ones. The first and the last column of the CCI matrix, namely the comparison of the
spectra at all concentrations with the spectra at MAX (blue box) and at MIN (green box), respectively, are isolated. The MPCC (yellow box) corresponds to the
fluconazole concentration at which the value of the MAX column is higher (>) than the value of the MIN column, at the same concentration. (B) MPCC breakpoint
determination. MPCC values of several susceptible (S1 to S5) and resistant (R1 to R5) strains from the same Candida spp. are compared. “>” indicates that the
spectra at the given concentration is more similar to the spectra at MAX, whereas “<” indicates that the spectra at the given concentration is more similar to the
spectra at MIN. The MPCC breakpoint concentration (S) correspond to the fluconazole concentration which allow the best discrimination between the resistant and
the susceptible strains (red box), as explained in De Carolis et al. (2012). (C) MALDI-TOF MS-based assay. A 3 × 3 CCI matrix is generated by comparing the spectra
at MAX, S, and MIN, as presented in Vella et al. (2013). The results of the correlation between S and MAX (blue box) and S and MIN (green box) are compared. The
strain is assessed as susceptible if the result of the correlation between S an MAX is higher than the result of the correlation between S and MIN (left matrix, personal
data), whereas the strain is assessed as resistant if the result of the correlation between S an MAX is lower than the result of the correlation between S and MIN (right
matrix, personal data).*Lohberger et al. (2014), FLC = fluconazole.
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FIGURE 2 | Proposition of C. auris outbreak management with MALDI-TOF MS. (A) Spectrum acquisition. A C. auris colony (here grown on Columbia medium) is
analyzed by MALDI-TOF MS to obtain a spectrum. (B) Identification. The spectrum obtained is compared to the reference spectra of the databases and an
identification Log(Score) is calculated. For fungal species, a proposed identification is accepted if the Log(Score) is equal or higher than 1.7. C. auris identification with
MALDI-TOF MS is already implemented but needs improvements. (C) AFST. Spectra obtained at different antifungal concentrations need to be compared to determine
the MPCC. From there, once the EUCAST and/or CLSI breakpoints have been defined, the MPCC breakpoint for C. auris and an antifungal drug can be determined,
allowing the AFST implementation. AFST with MALDI-TOF MS need to be adapted from existing protocols (Marinach et al., 2009; De Carolis et al., 2012; Vella et al.,
2013, 2017) to be used on C. auris. (D) Typing. Spectra of different C. auris strains originated from different clades and with different resistance mechanisms could be
compared to identify signature peaks specific to different resistance mechanisms or different clades. C. auris typing with MALDI-TOF MS needs to be developed.
CCI matrix to a 3 × 3 matrix (Figure 1C), including spectra
at maximal (MAX), null (MIN), and MPCC breakpoint (S)
drug concentrations. A yeast strain is diagnosed as resistant if
the CCI between S and MIN is higher than the CCI between
S and MAX (Vella et al., 2013). Finally, Vella et al. tested
their method on different drugs (caspofungin, anidulafungin,
and fluconazole) and different Candida spp (C. albicans and C.
glabrata). Even if they obtained partial success for the assessment
of the anidulafungin susceptibility (from 25 to 100% of accuracy,
depending on the mutated gene), they achieve a highly accurate
determination of the fluconazole and caspofungin susceptibilities
(more than 90% success; Vella et al., 2013, 2017).
Alternatively, a new MALDI-TOF MS-based susceptibility
assays was shown to accurately discriminate resistant from
susceptible strains in 6 h (Vatanshenassan et al., 2018). Indeed,
MALDI Biotyper antibiotic susceptibility test rapid assay (MBT-
ASTRA) was initially developed with bacteria and was able to
assess a susceptibility level depending on the cellular growth,
quantified by the peak intensities of theMALDI-TOFMS spectra.
Hence, a susceptible strain would display lower peaks intensities,
representing the lack of growth whereas resistant strains would
display higher peaks intensities as compared to an internal
standard (Sparbier et al., 2016). MBT-ASTRA was then adapted
to assess caspofungin susceptibility in C. albicans and C. glabrata,
with an accuracy ranging from 80 to 100% (Vatanshenassan et al.,
2018).
Thus, the reliability, accuracy and objectivity of the results
interpretation of MALDI-TOF MS-based assays offer advantages
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over other existing AFST methods. Moreover, the time saved
by both MALDI-TOF MS-based assays presented, with results
obtained in 3 to 15 h, in comparison to 48 h for other methods
(Posteraro and Sanguinetti, 2014), is crucial for clinicians.
However, to be optimal, both tools need further development
to be able to detect resistance to several antifungal drugs at a
time for a broader range of yeast species, in a simplified routine
use. To this end, kits and software should be combined and
developed to be more accessible and allow autonomous analyses
of results. Another lead might be the coupling of total laboratory
automation with MALDI-TOF MS in the classic workflow of
the diagnostic routine labs (Theparee et al., 2018). Nevertheless,
MALDI-TOF-MS is on the edge of becoming an indispensable
tool in the field of AFST.
MALDI-TOF MS for Typing
As we explained above, MALDI-TOF MS is a promising
tool for the detection of acquired antifungal resistance.
However, the previously presented MALDI-TOF MS-based
AFST assays require incubation with antifungal, which is
not easy in routine. Ideally, the susceptibility of a Candida
spp. strain should be determined directly by spectra sub-
typing, meaning detecting specific peaks associated with
resistance.
Therefore, the first step would be, as it was already done
for some bacteria (Manukumar and Umesha, 2017), to detect
specific peaks associated with the resistance or the susceptibility
to an antifungal drug (Posteraro et al., 2013). This aim is
promising since typing with MALDI-TOF MS was shown to be
able to cluster C. glabrata isolates according to their fluconazole
susceptibility profile (Dhieb et al., 2015) but no resistance nor
susceptibility peaks has yet been identified. In a further step,
identification of the resistance mechanism will further increase
the efficacy of the antifungal stewardship. Indeed, in the case of
diploid fungi such as C. albicans, a single copy GOF mutation
is sometimes phenotypically undetectable (Coste et al., 2006).
However, resistance can arise rapidly if the yeast becomes
homozygous for the resistance mutation or by increasing the
copy number of the gene carrying the GOFmutation (Coste et al.,
2006; Selmecki et al., 2010). Thus, we could detect resistance
mechanisms even before resistance is phenotypically expressed
hence improving antifungal stewardship. Moreover, typing with
MALDI-TOF MS could be used to track the geographical origin
of a strain, which is of great epidemiological value. To date, to the
authors’ knowledge, one single study in this field was reported for
fungi (Dhieb et al., 2015). However, this will be especially relevant
in the case of the threat generated by potential outbreak-causing
emerging fungi such as C. auris.
MALDI-TOF, A CRUCIAL TOOL TO
MANAGE THE EMERGING PATHOGEN
Candida auris
C. auris was first identified in Japan in 2009 (Satoh et al.,
2009). To date, four clades of C. auris have been identified
(Sarma and Upadhyay, 2017), impacting several countries in
the Americas, Africa, Asia, and Europe (Jeffery-Smith et al.,
2018). It quickly became a major clinical threat because of its
ability to spread from patient to patient in hospital settings
and its high level of antifungal resistance, classifying it as a
multidrug-resistant species (Lee et al., 2011; Schelenz et al., 2016;
Araúz et al., 2017). Moreover, C. auris infections are even more
complex to treat as they are often misdiagnosed (Jeffery-Smith
et al., 2018). Therefore, it is essential to rapidly identify and
determine antifungal susceptibility profile of C. auris isolates
to optimize patient care and implement appropriate hospital
hygiene measures.
To manage a C. auris outbreak, the first step is the
identification of the pathogen (Figures 2A,B). MALDI-TOF MS
has been proven to be the most accurate available method to
identify C. auris, surpassing all the other identification methods
(Jeffery-Smith et al., 2018). However, MALDI-TOF MS-based
identification still does not allow a sufficient identification rate,
leading to misdiagnosis (Chowdhary et al., 2017). This is due to
the lack of C. auris reference spectra in the databases (Mizusawa
et al., 2017). Nevertheless, this issue could be easily resolved
by increasing the number of reference spectra available (Jeffery-
Smith et al., 2018). Accordingly, Bruker recently released an
updated library, containing a total of 9 C. auris spectra, but only
in the Research Only Database (RUO).
Once a C. auris infection is confirmed, AFST need to be
regularly performed to detect the appearance of antifungal
resistance (Figure 2C). However, as no official clinical breakpoint
has yet been assessed for C. auris, either by EUCAST or CLSI
(CLSI, 2017; EUCAST, 2018), current AFST methods are unable
to accurately discriminate resistant from susceptible strains
(Jeffery-Smith et al., 2018). Therefore, since MALDI-TOF MS-
based AFST protocols have already been developed for several
drugs and Candida spp (Marinach et al., 2009; De Carolis
et al., 2012; Vella et al., 2013, 2017), once C. auris breakpoints
have been defined, MALDI-TOF MS-based protocols could be
adapted. Finally, MALDI-TOF MS-based typing could allow
identification of signature peaks associated with the different
clades or even strains, providing an easy tool to follow an
outbreak by tracking its origin and its evolution, linked to a
susceptibility profile, allowing a better antifungal management of
the outbreak (Figure 2D).
To conclude, fungal infections are challenging, especially
with the complications brought up by antifungal resistance.
However, MALDI-TOF MS has already revolutionized the
diagnosis of fungal infections and future developments
would bring new methods to assess the susceptibility
patterns of fungal infections, leading to a new era in clinical
mycology.
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